These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 24115369)

  • 41. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Tang H; Cui W; Li D; Wang T; Zhang J; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Jan; 19(1):142-147. PubMed ID: 27598833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urinary tract infections in patients with diabetes treated with dapagliflozin.
    Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
    J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis.
    Xu X; Xu W; Zhuo Q; Yan Y
    Ann Palliat Med; 2022 Mar; 11(3):1028-1037. PubMed ID: 35365032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
    Zheng XD; Qu Q; Jiang XY; Wang ZY; Tang C; Sun JY
    Am J Cardiovasc Drugs; 2021 May; 21(3):321-330. PubMed ID: 33001355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.
    Kosiborod M; Gause-Nilsson I; Xu J; Sonesson C; Johnsson E
    J Diabetes Complications; 2017 Jul; 31(7):1215-1221. PubMed ID: 28284707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2011 Oct; 13(10):928-38. PubMed ID: 21672123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
    Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
    J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
    Rosenstock J; Vico M; Wei L; Salsali A; List JF
    Diabetes Care; 2012 Jul; 35(7):1473-8. PubMed ID: 22446170
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Zhang YJ; Han SL; Sun XF; Wang SX; Wang HY; Liu X; Chen L; Xia L
    Medicine (Baltimore); 2018 Oct; 97(43):e12843. PubMed ID: 30412076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
    Ferrannini E; Ramos SJ; Salsali A; Tang W; List JF
    Diabetes Care; 2010 Oct; 33(10):2217-24. PubMed ID: 20566676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insights into efficacy and safety of dapagliflozin treatment for the management in older adults with type 2 diabetes: a systematic review and meta-analysis.
    Jiang L; Jia Y; Wang X; Wang Z; Lv X; Jia Y; Feng Y; Yin H; Yan M; Fan X; Liu Y
    Expert Opin Drug Saf; 2023; 22(5):407-416. PubMed ID: 36608279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
    Bailey CJ; Iqbal N; T'joen C; List JF
    Diabetes Obes Metab; 2012 Oct; 14(10):951-9. PubMed ID: 22776824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.